logo-loader

Hemogenyx Pharmaceuticals unveils new senior appointment

Published: 07:55 05 Nov 2018 GMT

1541404713_rsz_shutterstock_178464512
Chief operating officer Lawrence Pemble is leaving

HemoGenyx Pharmaceuticals PLC (LONHEMO) said that its chief operating officer is leaving as it unveiled a new senior appointment.

Lawrence Pemble is exiting immediately. Andrew Wright, meanwhile, is coming in as financial controller and company secretary, a “non-board position”.

Wright is a trained accountant who is currently the director of corporate development for Thomas Murray, a post-trade capital markets data and advisory firm and is an executive director of Trayned Insight, a data science company serving the healthcare and pharmaceutical industries.

Hemogenyx chief executive, Dr Vladislav Sandler, said: "I am delighted to welcome Andrew to the team and look forward to his support as we continue to advance the development of our novel therapeutic products for patients with blood and severe autoimmune diseases.

“I would also like to extend my thanks to Lawrence for his contribution to the board and we wish him well in his next ventures."

The company is developing technology that could transform bone marrow transplantation and the treatment of blood diseases.

Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it...

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) Dr Vladislav Sandler joins Proactive's Stephen Gunnion after the pre-clinical stage biopharmaceutical group raised £3.5 million, which will be utilized to progress its lead product candidate, Chimeric Antigen Receptor T-cells (HEMO-CAR-T), into...

6 days, 19 hours ago